Vericel Corp. (VCEL) Trading 10.5% Higher
Vericel Corp. (NASDAQ:VCEL)’s share price traded up 10.5% on Monday . The company traded as high as $2.60 and last traded at $2.43, with a volume of 425,421 shares. The stock had previously closed at $2.20.
The stock’s market capitalization is $50.71 million. The firm has a 50-day moving average price of $2.24 and a 200 day moving average price of $2.81.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/12/vericel-corp-vcel-trading-10-5-higher.html
Vericel Corp. (NASDAQ:VCEL) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.05. The firm had revenue of $12.80 million for the quarter, compared to analysts’ expectations of $15.05 million. On average, analysts expect that Vericel Corp. will post ($0.91) EPS for the current fiscal year.
Vericel Corp. Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vericel Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.